43 employees
CND Life Sciences develops an evidence-based tool to help confirm a diagnosis of synucleinopathy.
2017
$2.4M
from 1 investors over 1 rounds
CND Life Sciences raised $2.4M on October 26, 2020
Investors: National Institute of Neurological Disorders and Stroke (NINDS)